Last updated on May 2016

Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia


Brief description of study

This is a randomised double-blinded placebo-controlled multi centre study in 98 patients with ACPA positive arthralgia. The study is composed of 2 arms with a 1:1 randomisation at baseline: Treatment phase will be 6 months. Group 1: Abatacept s.c. 125 mg weekly for 6 months vs. Group 2: Placebo s.c. for 6 months. After 6 months both groups will run into the follow up period for another 12 months up to month 18. Patients developing arthritis will be treated according to local guidelines.

Clinical Study Identifier: NCT02778906

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Martin Fleck, Prof. Dr. med.

Klinikum Bad Abbach
Bad Abbach, Germany
  Connect »

Ramona Koenig, Dr. med.

Kerckhoff-Klinik Bad Nauheim
Bad Nauheim, Germany
  Connect »

Eugen Feist, Prof. Dr. med.

Charite Berlin
Berlin, Germany
  Connect »

Kirsten Karberg, Dr. med.

Praxis f r Rheumatologie und Innere Medizin
Berlin, Germany
  Connect »

Rieke Alten, Dr. med.

Schlosspark Klinik
Berlin, Germany
  Connect »

Martin Feuchtenberger, Dr. med.

Clinic Burghausen
Burghausen, Germany
  Connect »